CN104640865B - 作为激酶抑制剂的二氢吡咯烷子基-嘧啶 - Google Patents
作为激酶抑制剂的二氢吡咯烷子基-嘧啶 Download PDFInfo
- Publication number
- CN104640865B CN104640865B CN201380048493.XA CN201380048493A CN104640865B CN 104640865 B CN104640865 B CN 104640865B CN 201380048493 A CN201380048493 A CN 201380048493A CN 104640865 B CN104640865 B CN 104640865B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- compound
- cycloalkyl
- independently
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 **c1ncc(C(*)(*)N(C2)C(*II)=O)c2n1 Chemical compound **c1ncc(C(*)(*)N(C2)C(*II)=O)c2n1 0.000 description 7
- NMXRJWVVQWWXEU-PZYJYFCTSA-N C/C=C\C=C(\[C@@H](CO)NC(N(C1)C2(CCC2)c2c1nc(NC1CCOCC1)nc2)=O)/C#C Chemical compound C/C=C\C=C(\[C@@H](CO)NC(N(C1)C2(CCC2)c2c1nc(NC1CCOCC1)nc2)=O)/C#C NMXRJWVVQWWXEU-PZYJYFCTSA-N 0.000 description 1
- BKTXSVXCONQOAA-OAHLLOKOSA-N CC(C)(c(cn1)c(C2)nc1S(C)(=O)=O)N2C(N[C@H](CO)c1ccccc1)=O Chemical compound CC(C)(c(cn1)c(C2)nc1S(C)(=O)=O)N2C(N[C@H](CO)c1ccccc1)=O BKTXSVXCONQOAA-OAHLLOKOSA-N 0.000 description 1
- YAZULJUJKCJNKB-UHFFFAOYSA-N CC1(CO)NCC2NC(NC3CCOCC3)=NC=C12 Chemical compound CC1(CO)NCC2NC(NC3CCOCC3)=NC=C12 YAZULJUJKCJNKB-UHFFFAOYSA-N 0.000 description 1
- KBTAWWGYJCJSCV-UHFFFAOYSA-N CCCC(CC)OC(N1CC(C)CC1)=O Chemical compound CCCC(CC)OC(N1CC(C)CC1)=O KBTAWWGYJCJSCV-UHFFFAOYSA-N 0.000 description 1
- CRMPOXVAGBGAMB-UHFFFAOYSA-N CCCCC(C1)C1OC(N(C)C)N(C)C Chemical compound CCCCC(C1)C1OC(N(C)C)N(C)C CRMPOXVAGBGAMB-UHFFFAOYSA-N 0.000 description 1
- XPMIKUMIKAYOQP-UHFFFAOYSA-N CCCCOC(N(Cc1n2)C(C(OC)=O)c1cnc2SC)=O Chemical compound CCCCOC(N(Cc1n2)C(C(OC)=O)c1cnc2SC)=O XPMIKUMIKAYOQP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261702981P | 2012-09-19 | 2012-09-19 | |
| US61/702,981 | 2012-09-19 | ||
| PCT/US2013/060032 WO2014047020A1 (en) | 2012-09-19 | 2013-09-17 | Dihydropyrrolidino-pyrimidines as kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104640865A CN104640865A (zh) | 2015-05-20 |
| CN104640865B true CN104640865B (zh) | 2018-05-11 |
Family
ID=49274870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380048493.XA Active CN104640865B (zh) | 2012-09-19 | 2013-09-17 | 作为激酶抑制剂的二氢吡咯烷子基-嘧啶 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9546173B2 (enExample) |
| EP (1) | EP2897961B1 (enExample) |
| JP (1) | JP6186440B2 (enExample) |
| KR (1) | KR20150056550A (enExample) |
| CN (1) | CN104640865B (enExample) |
| AU (1) | AU2013318283A1 (enExample) |
| BR (1) | BR112015005982A2 (enExample) |
| CA (1) | CA2882410A1 (enExample) |
| EA (1) | EA201590600A1 (enExample) |
| ES (1) | ES2612885T3 (enExample) |
| IN (1) | IN2015DN01328A (enExample) |
| MX (1) | MX2015003535A (enExample) |
| WO (1) | WO2014047020A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104640865B (zh) * | 2012-09-19 | 2018-05-11 | 诺华股份有限公司 | 作为激酶抑制剂的二氢吡咯烷子基-嘧啶 |
| US11458124B2 (en) | 2018-07-12 | 2022-10-04 | UCBBiopharma Srl | Spirocyclic indane analogues as IL-17 modulators |
| WO2020243457A1 (en) * | 2019-05-29 | 2020-12-03 | Viogen Biosciences, Llc | Compounds and therapeutic uses thereof |
| CN114502546A (zh) * | 2019-08-01 | 2022-05-13 | 普拉特戈公司 | 晚期糖基化终产物的抑制剂 |
| ES3018143T3 (en) * | 2019-12-10 | 2025-05-14 | Hoffmann La Roche | New braf inhibitors as paradox breakers |
| IL292161B2 (en) | 2019-12-10 | 2025-04-01 | Hoffmann La Roche | New methylquinazolinone derivatives |
| JP7296017B2 (ja) * | 2020-04-30 | 2023-06-21 | メッドシャイン ディスカバリー インコーポレイテッド | ベンゾスルタムを含む化合物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004007468A1 (en) * | 2002-07-15 | 2004-01-22 | Merck & Co., Inc. | Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| WO2005068468A2 (en) * | 2003-12-02 | 2005-07-28 | Vertex Pharmaceuticals, Inc. | Heterocyclic protein kinase inhibitors and uses thereof |
| PE20060426A1 (es) | 2004-06-02 | 2006-06-28 | Schering Corp | DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa |
| SI1838718T1 (sl) | 2005-01-10 | 2011-08-31 | Pfizer | Pirolopirazoli, zmogljivi inhibitorji kinaze |
| SI1966151T1 (sl) | 2005-12-13 | 2012-02-29 | Schering Corp | Policikliäśni indazol derivati, ki so erk inhibitorji |
| MY148609A (en) | 2007-06-05 | 2013-05-15 | Merck Sharp & Dohme | Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer |
| WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| EP2615916B1 (en) * | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel erk inhibitors |
| JP2013542965A (ja) | 2010-11-17 | 2013-11-28 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 腫瘍の治療方法 |
| ES2543050T3 (es) | 2011-02-28 | 2015-08-14 | Array Biopharma, Inc. | Inhibidores de serina/treonina quinasa |
| JP2015508785A (ja) | 2012-03-02 | 2015-03-23 | ジェネンテック， インコーポレイテッド | ピリジニル及びピリミジニルスルホキシド及びスルホン誘導体 |
| CN104640865B (zh) * | 2012-09-19 | 2018-05-11 | 诺华股份有限公司 | 作为激酶抑制剂的二氢吡咯烷子基-嘧啶 |
-
2013
- 2013-09-17 CN CN201380048493.XA patent/CN104640865B/zh active Active
- 2013-09-17 EP EP13771007.5A patent/EP2897961B1/en active Active
- 2013-09-17 CA CA2882410A patent/CA2882410A1/en not_active Abandoned
- 2013-09-17 WO PCT/US2013/060032 patent/WO2014047020A1/en not_active Ceased
- 2013-09-17 JP JP2015533126A patent/JP6186440B2/ja active Active
- 2013-09-17 KR KR1020157006602A patent/KR20150056550A/ko not_active Withdrawn
- 2013-09-17 EA EA201590600A patent/EA201590600A1/ru unknown
- 2013-09-17 ES ES13771007.5T patent/ES2612885T3/es active Active
- 2013-09-17 MX MX2015003535A patent/MX2015003535A/es unknown
- 2013-09-17 US US14/428,546 patent/US9546173B2/en active Active
- 2013-09-17 IN IN1328DEN2015 patent/IN2015DN01328A/en unknown
- 2013-09-17 AU AU2013318283A patent/AU2013318283A1/en not_active Abandoned
- 2013-09-17 BR BR112015005982A patent/BR112015005982A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2897961B1 (en) | 2016-10-26 |
| CN104640865A (zh) | 2015-05-20 |
| MX2015003535A (es) | 2015-07-14 |
| EP2897961A1 (en) | 2015-07-29 |
| WO2014047020A1 (en) | 2014-03-27 |
| CA2882410A1 (en) | 2014-03-27 |
| EA201590600A1 (ru) | 2015-07-30 |
| AU2013318283A1 (en) | 2015-03-05 |
| US9546173B2 (en) | 2017-01-17 |
| JP2015529248A (ja) | 2015-10-05 |
| JP6186440B2 (ja) | 2017-08-23 |
| KR20150056550A (ko) | 2015-05-26 |
| US20150274733A1 (en) | 2015-10-01 |
| IN2015DN01328A (enExample) | 2015-07-03 |
| BR112015005982A2 (pt) | 2017-07-04 |
| ES2612885T3 (es) | 2017-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104640865B (zh) | 作为激酶抑制剂的二氢吡咯烷子基-嘧啶 | |
| ES2648143T3 (es) | Derivados de 5,6-dihidro-imidazo[1,2-a]pirazin-8-ilamina útiles como inhibidores de la beta-secretasa (BACE) | |
| BR112020019264A2 (pt) | Compostos para tratar doença de huntington | |
| KR20210018199A (ko) | 이카로스의 분해를 위한 세레블론 결합제 | |
| TWI596095B (zh) | Dihydropyridazine-3,5-dione derivatives | |
| KR20210044822A (ko) | 피롤로피리미딘 itk 억제제 | |
| WO2018057884A1 (en) | Shp2 phosphatase inhibitors and methods of use thereof | |
| CN105939997A (zh) | 作为dlk抑制剂的吡唑衍生物及其用途 | |
| AU2012206555A1 (en) | Oxazine derivatives and their use in the treatment of neurological disorders | |
| WO2018066718A1 (en) | Therapeutic compounds | |
| CN116685585A (zh) | 一种高活性的hpk1激酶抑制剂 | |
| CN112313220B (zh) | Pd-l1拮抗剂化合物 | |
| AU2023330130A1 (en) | Compounds and methods for modulating her2 | |
| CN117529476A (zh) | 取代的1,2-二氨基杂环化合物衍生物的制备及其作为药剂的用途 | |
| AU2020350211B2 (en) | MLL1 inhibitors and anti-cancer agents | |
| TW202304906A (zh) | 高活性hpk1激酶抑制劑 | |
| CN116783205A (zh) | 用于通过泛素蛋白酶体途径降解细胞周期蛋白依赖性激酶2的化合物 | |
| RU2852021C2 (ru) | Новые ингибиторы JAK1-киназ | |
| EP4536642A1 (en) | Heterocyclic compounds as pi3ka inhibitors | |
| WO2023025225A1 (zh) | 细胞周期蛋白k降解剂 | |
| WO2025165942A1 (en) | Tricyclic compounds as parc inhibitors | |
| CN116249696A (zh) | 嘧啶酮类化合物及其用途 | |
| HK40091563A (zh) | 嘧啶酮类化合物及其用途 | |
| WO2024229401A2 (en) | Diazepino-thieno-quinoxaline compounds and their use in therapy | |
| HK40064126B (zh) | 作为src同源-2磷酸酶抑制剂的稠合的三环衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |